• CGM Without Insulin: 82% of Non-Insulin Type 2 Diabetes Patients Improved Hyperglycemia (ADA 2026)
    Nov 12 2026

    CGM without insulin is changing type 2 diabetes care. A 2026 study presented at the American Diabetes Association's annual meeting found that 82% of adults with Type 2 diabetes not on insulin substantially reduced hyperglycemia using CGM. This episode explores how CGM without insulin works, why non-insulin type 2 diabetes monitoring matters, and what this means for the newly diagnosed and those managing with oral medications. We cover over-the-counter CGM options for non-insulin users, barriers to access, and how to overcome them. If you thought CGM was only for insulin users, this episode will change everything.

    Institutional AI Design • Agent-to-Agent Era

    Episode Highlights

    • The study population: adults with T2D not using insulin.
    • How CGM reduced hyperglycemia without insulin therapy.
    • Implications for the newly diagnosed and those managing with oral medications.
    • Over-the-counter CGM options for non-insulin users.
    • Barriers to access and how to overcome them.
    • Why CGM without insulin is becoming a core question in type 2 diabetes monitoring.

    Key Studies Referenced

    • 2026 ADA annual meeting study: 82% of non-insulin-treated adults with T2D substantially reduced hyperglycemia using CGM.
    • Analysis of CGM use in non-insulin type 2 diabetes and implications for oral medication management.
    • Real-world barriers to CGM access for non-insulin users and emerging over-the-counter options.

    Resources & Links

    Research Source – PubMed: CGM Without Insulin PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=CGM+without+insulin+type+2+diabetes)

    AI Glucose Blood Monitoring App: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AI A2A HUB – Free Test Results Interpretation: AIDevMD (https://aidevmd.com/)

    Diabetes Support Group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact the Host: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript Teaser: “In this transcript, we unpack CGM without insulin: why 82% of non-insulin type 2 diabetes patients improved hyperglycemia, and what that means for monitoring, oral medications, and access.”

    SEO Keywords: CGM without insulin, non-insulin type 2 diabetes monitoring, hyperglycemia reduction, type 2 diabetes CGM, over-the-counter CGM, ADA 2026, continuous glucose monitor, diabetes technology, oral medication diabetes, CGM access, Sugar Level app, diabetes support.

    Medical Disclaimer: This podcast and description are for educational and informational purposes only and do not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions about a medical condition, medication, CGM use, diet, exercise, or diabetes management. Never disregard professional medical advice or delay seeking it because of something you heard or read here. Individual results may vary. The studies referenced do not imply that any app, product, or service can replace medical care. If you have type 1 diabetes, use insulin, are pregnant, or have other health conditions, consult your clinician before changing monitoring, food, activity, or medication.

    Show More Show Less
    32 mins
  • CGM vs Fingerstick: What the FreeDM2 Trial Really Means for Basal Insulin Users
    Nov 5 2026

    FreeDM2 trial: CGM vs fingerstick — a landmark 2026 randomized controlled trial across 24 UK centers just proved what many suspected: real-time CGM beats self-monitoring of blood glucose for people on basal insulin, and the gap only widens over time. In this episode, we break down the FreeDM2 trial design: 303 adults with type 2 diabetes on basal insulin plus SGLT2i or GLP-1 RA. HbA1c results at 16 weeks and 32 weeks show the CGM group dropping to 7.8% vs. 8.3% in the fingerstick arm. We explain why the benefit persisted during both self-management and clinician-supported phases, why severe hypoglycemia occurred twice in the SMBG control group and zero times in the CGM group, and what this means for insurance coverage, clinical practice, and real-time CGM type 2 diabetes care.

    Institutional AI Design • Agent-to-Agent Era

    Episode Highlights

    • FreeDM2 trial design: 303 adults, basal insulin plus SGLT2i or GLP-1 RA.
    • HbA1c results at 16 weeks and 32 weeks: CGM group drops to 7.8% vs. 8.3%.
    • Why the benefit persisted during both self-management and clinician-supported phases.
    • Severe hypoglycemia rates: two instances in the SMBG control group, none in CGM.
    • What this means for insurance coverage and clinical practice.
    • Why real-time CGM vs fingerstick is now a central question in type 2 diabetes care.

    Key Studies Referenced

    • FreeDM2 trial: 2026 randomized controlled trial across 24 UK centers.
    • 303 adults with type 2 diabetes on basal insulin plus SGLT2i or GLP-1 RA.
    • HbA1c at 16 and 32 weeks: real-time CGM vs self-monitoring of blood glucose.
    • Severe hypoglycemia: two events in the SMBG control group, zero in the CGM group.

    Resources & Links

    Research Source – PubMed: FreeDM2 Trial PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=FreeDM2+trial+CGM+fingerstick)

    AI Glucose Blood Monitoring App: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AI A2A HUB – Free Test Results Interpretation: AIDevMD (https://aidevmd.com/)

    Diabetes Support Group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact the Host: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript Teaser: “In this transcript, we unpack the FreeDM2 trial: CGM vs fingerstick — and why real-time CGM type 2 diabetes management just got its strongest evidence yet.”

    SEO Keywords: FreeDM2 trial, CGM vs fingerstick, real-time CGM type 2 diabetes, basal insulin, SGLT2i, GLP-1 RA, HbA1c 7.8 vs 8.3, severe hypoglycemia, continuous glucose monitor, diabetes technology, CGM insurance coverage, type 2 diabetes clinical trial.

    Medical Disclaimer: This podcast and description are for educational and informational purposes only and do not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions about a medical condition, medication, CGM use, diet, exercise, or diabetes management. Never disregard professional medical advice or delay seeking it because of something you heard or read here. Individual results may vary. The studies referenced do not imply that any app, product, or service can replace medical care. If you have type 1 diabetes, use insulin, are pregnant, or have other health conditions, consult your clinician before changing monitoring, food, activity, or medication.

    Show More Show Less
    23 mins
  • The Digital Twin That Texts You: AI Diabetes Self-Management Beyond the Clinic
    Oct 29 2026

    Can a digital twin diabetes system text you personalized feedback between clinic visits? A 2026 npj Health Systems study tested a human-in-the-loop AI predictive digital twin that sends daily SMS feedback to adults with Type 2 diabetes. The results suggest this could scale precision diabetes care beyond the clinic. In this episode, we explain what a digital twin means in diabetes management, how the human-in-the-loop design combines AI predictions with clinician oversight, and what 6,467 longitudinal data points across weight, diet, activity, and glucose reveal. We also explore personalized SMS feedback as a scalable intervention and how AI diabetes self-management can extend precision diabetes support between visits.

    The Diabetes Control Loop: Lifestyle, Habits and Glucose Monitoring

    In this episode:

    • What a “digital twin” means in diabetes management.
    • The human-in-the-loop design: AI predictions plus clinician oversight.
    • 6,467 longitudinal data points across weight, diet, activity, and glucose.
    • Personalized SMS feedback as a scalable intervention.
    • Extending precision diabetes support beyond clinic visits.

    Sources and tools:

    PubMed search: Digital twin diabetes AI (https://pubmed.ncbi.nlm.nih.gov/?term=digital+twin+diabetes+AI)

    Sugar Level app: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AIDevMD: Free test results interpretation (https://aidevmd.com/)

    Support group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript teaser: “In this transcript, we unpack digital twin diabetes: how an AI predictive digital twin texts personalized feedback between visits, and what it means for precision diabetes care and AI diabetes self-management.”

    Medical disclaimer: This episode is for education only and is not medical advice, diagnosis, or treatment. Always consult your physician or qualified health provider about your condition, medications, CGM use, diet, exercise, or diabetes management. Never stop or change medication without professional guidance. Individual results vary, and the studies discussed do not replace medical care.

    Show More Show Less
    43 mins
  • Generative AI Diabetes: GluFormer Predicts Cardiovascular Death From Your CGM Data
    Oct 22 2026

    What if a generative AI diabetes model could read your CGM data and predict your long-term future? A 2026 Nature study introduced GluFormer, a generative foundation model that extracts powerful predictive features from short-term CGM data and uses them for CGM risk prediction — stratifying long-term disease risk, including diabetes complications and cardiovascular death. In this episode, we explain what a generative foundation model is and why it matters for diabetes, how GluFormer predicts glycemic parameters from CGM data, and how it separates short-term glucose prediction from long-term risk forecasting. We also cover the ethical and practical considerations for AI-driven diabetes care, and what this means for anyone wearing a continuous glucose monitor.

    The Diabetes Control Loop: Lifestyle, Habits and Glucose Monitoring

    In this episode:

    • What a generative foundation model is and why it matters for diabetes.
    • How GluFormer predicts glycemic parameters from CGM data.
    • Long-term risk stratification: diabetes, cardiovascular death, and more.
    • The difference between short-term glucose prediction and long-term risk forecasting.
    • Ethical and practical considerations for AI-driven diabetes care.

    Sources and tools:

    PubMed search: GluFormer generative AI CGM (https://pubmed.ncbi.nlm.nih.gov/?term=GluFormer+generative+AI+CGM)

    Sugar Level app: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AIDevMD: Free test results interpretation (https://aidevmd.com/)

    Support group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript teaser: “In this transcript, we unpack GluFormer: generative AI diabetes meets CGM risk prediction — how a foundation model forecasts long-term cardiovascular and metabolic risk from short-term glucose data.”

    Medical disclaimer: This episode is for education only and is not medical advice, diagnosis, or treatment. Always consult your physician or qualified health provider about your condition, medications, CGM use, diet, exercise, or diabetes management. Never stop or change medication without professional guidance. Individual results vary, and the studies discussed do not replace medical care.

    Show More Show Less
    50 mins
  • Early Combination Therapy T2D: Why Waiting to Escalate Treatment May Be a Mistake
    Oct 15 2026

    Is waiting to escalate type 2 diabetes treatment a mistake? New 2026 research suggests that early combination therapy T2D — hitting the disease hard and early — may protect your heart and kidneys better than the traditional step-by-step approach. In this episode, we break down the old paradigm of metformin first and adding drugs one by one, and contrast it with the new thinking: early cardio-renal-metabolic risk reduction. You’ll learn when to consider SGLT2 inhibitors, GLP-1 receptor agonists, or tirzepatide as first-line add-ons, how individualized treatment targets are shaping 2026 guidelines, and the exact questions to ask your endocrinologist about early combination therapy.

    The Diabetes Control Loop: Lifestyle, Habits and Glucose Monitoring

    In this episode:

    • The old paradigm: metformin first, then add drugs one by one.
    • The new thinking: early cardio-renal-metabolic risk reduction.
    • When to consider SGLT2i, GLP-1 RA, or tirzepatide as first-line add-ons.
    • The role of individualized treatment targets in 2026.
    • Questions to ask your endocrinologist about early combination.

    Sources and tools:

    PubMed search: Early combination therapy T2D PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=early+combination+therapy+type+2+diabetes)

    Sugar Level app: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AIDevMD: Free test results interpretation (https://aidevmd.com/)

    Support group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript teaser: “In this transcript, we unpack early combination therapy T2D: why early intervention with SGLT2i, GLP-1 RA, or tirzepatide may rewrite cardio-renal protection in type 2 diabetes.”

    Medical disclaimer: This episode is for education only and is not medical advice, diagnosis, or treatment. Always consult your physician or qualified health provider about your condition, medications, diet, exercise, or diabetes management. Never stop or change medication without professional guidance. Individual results vary, and the studies discussed do not replace medical care.

    Show More Show Less
    48 mins
  • Mediterranean Diet Type 2 Diabetes: What 6 Counseling Sessions Can Do for Blood Sugar
    Oct 8 2026

    Mediterranean diet type 2 diabetes — forget restrictive fad diets. A structured Mediterranean diet intervention delivered in just six clinical sessions produced measurable metabolic improvements that lasted a full year. This episode breaks down what the Mediterranean diet actually looks like in practice, why nutrition counseling frequency matters more than intensity, and how personalized aerobic and resistance training alongside diet amplifies results. We explore visceral fat reduction as the hidden metric that predicts metabolic health, and we show you how to ask your doctor for a referral to a lifestyle medicine program. If you’re managing type 2 diabetes and want evidence-based nutrition counseling diabetes strategies, this is the episode for you.

    Institutional AI Design • Agent-to-Agent Era

    Episode Highlights

    • What the Mediterranean diet actually looks like in practice.
    • Why nutrition counseling frequency matters more than intensity.
    • The role of personalized aerobic and resistance training alongside diet.
    • Visceral fat reduction: the hidden metric that predicts metabolic health.
    • How to ask your doctor for a referral to a lifestyle medicine program.
    • Why Mediterranean diet type 2 diabetes strategies are now a first-line lifestyle conversation.

    Key Studies Referenced

    • Structured Mediterranean diet intervention delivered in six clinical sessions.
    • Metabolic improvements sustained at 12 months.
    • Personalized aerobic and resistance training combined with diet.
    • Visceral fat reduction as a predictor of metabolic health in type 2 diabetes.

    Resources & Links

    Research Source – PubMed: Mediterranean Diet Type 2 Diabetes PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=Mediterranean+diet+type+2+diabetes+nutrition+counseling)

    AI Glucose Blood Monitoring App: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AI A2A HUB – Free Test Results Interpretation: AIDevMD (https://aidevmd.com/)

    Diabetes Support Group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact the Host: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript Teaser: “In this transcript, we unpack Mediterranean diet type 2 diabetes: what 6 counseling sessions can do, why nutrition counseling diabetes matters, and how visceral fat reduction predicts metabolic health.”

    Mediterranean diet type 2 diabetes, nutrition counseling diabetes, visceral fat reduction, type 2 diabetes diet, lifestyle medicine program, aerobic training diabetes, resistance training diabetes, blood sugar control, diabetes nutrition, metabolic health, Sugar Level app, diabetes support.

    Medical Disclaimer: This podcast and description are for educational and informational purposes only and do not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions about a medical condition, medication, CGM use, diet, exercise, or diabetes management. Never disregard professional medical advice or delay seeking it because of something you heard or read here. Individual results may vary. The studies referenced do not imply that any app, product, or service can replace medical care. If you have type 1 diabetes, use insulin, are pregnant, or have other health conditions, consult your clinician before changing monitoring, food, activity, or medication.

    Show More Show Less
    41 mins
  • 100% Type 2 Diabetes Remission Without Drugs: The 2025 Canadian Lifestyle Program
    Oct 1 2026

    Type 2 diabetes remission is real—and a 2025 Canadian clinical program achieved it in every single drug-naive participant who completed it. The secret wasn't a miracle drug; it was the Mediterranean diet and personalized exercise. This episode unpacks the 12-month multidisciplinary program: 6 nutrition counseling sessions plus personalized aerobic and resistance training. We cover the body weight reduction of 4.8 kg and waist circumference drop of 6.3 cm, the 100% remission rate among drug-naive T2D participants at 12 months, and how 67% of T2D participants on glucose-lowering agents achieved A1C <6.5%. We also discuss why no prediabetes participants progressed to T2D during the intervention. If you want to understand type 2 diabetes remission, Mediterranean diet diabetes strategies, and lifestyle intervention T2D, this episode is for you.

    Institutional AI Design • Agent-to-Agent Era

    Episode Highlights

    • The 12-month multidisciplinary program: 6 nutrition counseling sessions plus personalized aerobic/resistance training.
    • Body weight reduction of 4.8 kg and waist circumference drop of 6.3 cm.
    • 100% remission rate among drug-naive T2D participants at 12 months.
    • 67% of T2D participants on glucose-lowering agents achieved A1C <6.5%.
    • No prediabetes participants progressed to T2D during the intervention.
    • Why type 2 diabetes remission is now a realistic goal with lifestyle intervention T2D.

    Key Studies Referenced

    • 2025 Canadian clinical program: 12-month multidisciplinary lifestyle intervention for T2D remission.
    • 6 nutrition counseling sessions plus personalized aerobic and resistance training.
    • 100% remission in drug-naive T2D participants; 67% of those on glucose-lowering agents reached A1C <6.5%.
    • No progression from prediabetes to T2D during the intervention.

    Resources & Links

    Research Source – PubMed: Type 2 Diabetes Remission PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=type+2+diabetes+remission+Mediterranean+diet+lifestyle+intervention)

    AI Glucose Blood Monitoring App: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AI A2A HUB – Free Test Results Interpretation: AIDevMD (https://aidevmd.com/)

    Diabetes Support Group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact the Host: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript Teaser: “In this transcript, we unpack type 2 diabetes remission: the 2025 Canadian lifestyle program, Mediterranean diet diabetes results, and why 100% of drug-naive participants got off medication.”

    SEO Keywords: type 2 diabetes remission, Mediterranean diet diabetes, lifestyle intervention T2D, drug-naive type 2 diabetes, A1C below 6.5, diabetes reversal, weight loss diabetes, waist circumference, prediabetes prevention, Canadian diabetes program, diabetes nutrition counseling, resistance training diabetes, Sugar Level app, diabetes support.

    Medical Disclaimer: This podcast and description are for educational and informational purposes only and do not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions about a medical condition, medication, CGM use, diet, exercise, or diabetes management. Never disregard professional medical advice or delay seeking it because of something you heard or read here. Individual results may vary. The studies referenced do not imply that any app, product, or service can replace medical care. If you have type 1 diabetes, use insulin, are pregnant, or have other health conditions, consult your clinician before changing monitoring, food, activity, or medication.

    Show More Show Less
    40 mins
  • ADA 2026 Guidelines: Why CGM for Type 2 Diabetes Is Now Recommended for Almost Everyone
    Sep 24 2026

    CGM for type 2 diabetes just became the standard of care. In 2026, the American Diabetes Association dropped a bombshell—CGM is now recommended for virtually everyone with diabetes, not just those on insulin. This episode unpacks the ADA 2026 guidelines and what they mean for you. We explain the difference between real-time CGM, professional CGM, and over-the-counter devices like Stelo and Lingo. We discuss why real-time CGM replaced intermittently scanned CGM in the ADA technology tables, what “Time in Range” means and why it’s becoming as important as A1C, and how to talk to your doctor about getting a CGM prescription. If you have type 2 diabetes, this is the episode that will bring you up to speed on the biggest change in diabetes technology this year.

    Institutional AI Design • Agent-to-Agent Era

    Episode Highlights

    • The 2026 ADA Standards of Care update making CGM the recognized standard of care.
    • Difference between real-time CGM, professional CGM, and over-the-counter devices like Stelo and Lingo.
    • Why real-time CGM replaced intermittently scanned CGM in the ADA technology tables.
    • What “Time in Range” means and why it’s becoming as important as A1C.
    • How to talk to your doctor about getting a CGM prescription.
    • Why CGM for type 2 diabetes is now a mainstream recommendation, not a niche tool.

    Key Studies Referenced

    • ADA 2026 Standards of Care: CGM recommended for virtually everyone with diabetes.
    • ADA technology tables: real-time CGM replaces intermittently scanned CGM.
    • Time in Range as a growing metric alongside A1C in diabetes management.

    Resources & Links

    Research Source – PubMed: CGM for Type 2 Diabetes PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=CGM+for+type+2+diabetes+ADA+2026+guidelines)

    AI Glucose Blood Monitoring App: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AI A2A HUB – Free Test Results Interpretation: AIDevMD (https://aidevmd.com/)

    Diabetes Support Group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact the Host: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript Teaser: “In this transcript, we unpack CGM for type 2 diabetes: the 2026 ADA guidelines, Time in Range, real-time CGM vs over-the-counter devices, and how to get a prescription.”

    SEO Keywords: CGM for type 2 diabetes, ADA 2026 guidelines, Time in Range, real-time CGM, professional CGM, over-the-counter CGM, Stelo, Lingo, continuous glucose monitor, diabetes technology, CGM prescription, type 2 diabetes management, intermittently scanned CGM, Sugar Level app, diabetes support.

    Medical Disclaimer: This podcast and description are for educational and informational purposes only and do not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions about a medical condition, medication, CGM use, diet, exercise, or diabetes management. Never disregard professional medical advice or delay seeking it because of something you heard or read here. Individual results may vary. The studies referenced do not imply that any app, product, or service can replace medical care. If you have type 1 diabetes, use insulin, are pregnant, or have other health conditions, consult your clinician before changing monitoring, food, activity, or medication.

    Show More Show Less
    52 mins